Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (16186)
All Articles published online
|
Publishing Process of This Article
|
Feb 21, 2019 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i7/789.htm |
| Number | Citing Articles |
| 1 |
John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Muhammad Shaalan Beg, Steven T. Brower, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, William P. Harris, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jennifer J. Knox, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Rachna T. Shroff, Davendra P.S. Sohal, Tamar H. Taddei, Neeta K. Venepalli, Andrea Wilson, Andrew X. Zhu, Michal G. Rose. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology 2020; 38(36): 4317 doi: 10.1200/JCO.20.02672
|
| 2 |
Chih-Chieh Yen, Chia-Jui Yen. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety 2022; 21(2): 157 doi: 10.1080/14740338.2022.1995353
|
| 3 |
Hiroji Shinkawa, Shogo Tanaka, Shigekazu Takemura, Ryosuke Amano, Kenjiro Kimura, Masahiko Kinoshita, Kanae Takahashi, Shuichiro Matsuzaki, Shoji Kubo. Nomograms predicting extra- and early intrahepatic recurrence after hepatic resection of hepatocellular carcinoma. Surgery 2021; 169(4): 922 doi: 10.1016/j.surg.2020.10.012
|
| 4 |
Hui Zeng, Qi Xu, Jinyu Wang, Xiaoqing Xu, Jun Luo, Lei Zhang, Cong Luo, Jieer Ying, Jingjing Li. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1073133
|
| 5 |
Jilin Wang, Teddy Yang, Jie Xu. Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology 2020; 1248: 619 doi: 10.1007/978-981-15-3266-5_23
|
| 6 |
Yarong Guo, Jun Xu, Qiang Du, Yihe Yan, David A. Geller. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin. Translational Oncology 2021; 14(6): 101059 doi: 10.1016/j.tranon.2021.101059
|
| 7 |
Bing Jiang, Longfei Feng, Tao Yang, Wenjing Guo, Yangyang Li, Tao Wang, Chengguang Liu, Haixiang Su. Combination of chloroquine diphosphate and salidroside induces human liver cell apoptosis via regulation of mitochondrial dysfunction and autophagy. Molecular Medicine Reports 2022; 27(2) doi: 10.3892/mmr.2022.12924
|
| 8 |
Wafaa M. Rashed, Mohamed Ahmed Mohamed Kandeil, Mohamed O. Mahmoud, Sameera Ezzat. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. Journal of the Egyptian National Cancer Institute 2020; 32(1) doi: 10.1186/s43046-020-0016-x
|
| 9 |
Aiqing Ma, Rui Zhang. <p>Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer</p>. Cancer Management and Research 2020; : 3537 doi: 10.2147/CMAR.S240064
|
| 10 |
Richard S. Finn, Masatoshi Kudo, Ann-Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean-Frederic Blanc, Ari D. Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang-Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, Thomas R. Jeffry Evans. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clinical Cancer Research 2021; 27(17): 4848 doi: 10.1158/1078-0432.CCR-20-4219
|
| 11 |
Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.790963
|
| 12 |
Keigo Murakami, Hiroyuki Kumata, Shigehito Miyagi, Takashi Kamei, Hironobu Sasano. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma. Pathology International 2021; 71(10): 682 doi: 10.1111/pin.13149
|
| 13 |
Guangjiang Jiang, Sunbin Ling, Qifan Zhan, Li Zhuang, Xiao Xu. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplantation Reviews 2021; 35(2): 100606 doi: 10.1016/j.trre.2021.100606
|
| 14 |
Ruimin Liu, Yan Sun, Shuai Chen, Yun Hong, Zhongxian Lu. FOXD3 and GAB2 as a pair of rivals antagonistically control hepatocellular carcinogenesis. The FEBS Journal 2022; 289(15): 4536 doi: 10.1111/febs.16403
|
| 15 |
Chai Hong Rim, Won Jae Lee, Bekhzood Musaev, Ten Yakov Volichevich, Ziyayev Yakhyo Pazlitdinovich, Tillysshaykhov Mirzagaleb Nigmatovich, Jae Suk Rim. Challenges and Suggestions in Management of Lung and Liver Cancer in Uzbekistan: The Second Report of the Uzbekistan–Korea Oncology Consortium. International Journal of Environmental Research and Public Health 2022; 19(18): 11727 doi: 10.3390/ijerph191811727
|
| 16 |
Hendra Susanto, Chih-Hong Wang, Aulanni’am Aulanni’am, Adeodatus Yuda Handaya. Enhancing early stage of hepatocellular carcinoma: Does correlate to MicroRNA 122 and miR196a interaction?. INTERNATIONAL CONFERENCE ON BIOLOGY AND APPLIED SCIENCE (ICOBAS) 2019; 2120: 070021 doi: 10.1063/1.5115738
|
| 17 |
Tao Ma, Yue Ma, Yongjun Du, Zhongheng Wei, Jianchu Wang, Yufu Jun, Fenqiang Xiao. RETRACTED: Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.585172
|
| 18 |
John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, Michal G. Rose. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of Clinical Oncology 2024; 42(15): 1830 doi: 10.1200/JCO.23.02745
|
| 19 |
Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang. The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy. Biomarker Research 2025; 13(1) doi: 10.1186/s40364-024-00722-6
|
| 20 |
Marcin Cybulski, Katarzyna Sidoryk, Magdalena Zaremba-Czogalla, Bartosz Trzaskowski, Marek Kubiszewski, Joanna Tobiasz, Anna Jaromin, Olga Michalak. The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations. International Journal of Molecular Sciences 2024; 25(5): 2573 doi: 10.3390/ijms25052573
|
| 21 |
A. D. Darenskaya, A. A. Rumyantsev, S. L. Gutorov, A. S. Tyulyandina. Evolution of systemic therapy for disseminated endometrial cancer: literature review. Malignant tumours 2023; 13(2): 80 doi: 10.18027/2224-5057-2023-13-2-6
|
| 22 |
Antonella Argentiero, Antonella Delvecchio, Rossella Fasano, Alessandro Andriano, Ingrid Catalina Caradonna, Riccardo Memeo, Vanessa Desantis. The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments. Journal of Clinical Medicine 2023; 12(23): 7469 doi: 10.3390/jcm12237469
|
| 23 |
Yu‐Chi Lee, Jing‐Houng Wang, Chien‐Hung Chen, Chao‐Hung Hung, Kai‐Che Lo, Yi‐Hao Yen, Kwong‐Ming Kee, Tsung‐Hui Hu, Sheng‐Nan Lu, Yuan‐Hung Kuo. Sorafenib use in hepatitis B virus‐ or hepatitis C virus‐related hepatocellular carcinoma: A propensity score matching study. The Kaohsiung Journal of Medical Sciences 2021; 37(10): 894 doi: 10.1002/kjm2.12413
|
| 24 |
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. International Journal of Molecular Sciences 2019; 20(19): 4811 doi: 10.3390/ijms20194811
|
| 25 |
Jian Xu, Xiaomin Shen, Bo Zhang, Rui Su, Mingxuan Cui, Lihua Yan, Yu Cao. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma. Bioscience Reports 2021; 41(9) doi: 10.1042/BSR20211053
|
| 26 |
Xu-Feng Zhang, Timothy M. Pawlik. ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology 2021; 28(12): 7634 doi: 10.1245/s10434-021-10163-2
|
| 27 |
Katharina Pomej, Lorenz Balcar, Bernhard Scheiner, Georg Semmler, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Christian Müller, Michael Trauner, Matthias Pinter. Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Journal of Hepatocellular Carcinoma 2021; : 1485 doi: 10.2147/JHC.S317957
|
| 28 |
Jiang Chen, Dan G. Duda. Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms. EBioMedicine 2020; 52: 102644 doi: 10.1016/j.ebiom.2020.102644
|
| 29 |
Sheik Aliya, Hoomin Lee, Munirah Alhammadi, Reddicherla Umapathi, Yun Huh. An Overview on Single-Cell Technology for Hepatocellular Carcinoma Diagnosis. International Journal of Molecular Sciences 2022; 23(3): 1402 doi: 10.3390/ijms23031402
|
| 30 |
Xue Li, Xiaodong Sun, Chengxia Kan, Bing Chen, Na Qu, Ningning Hou, Yongping Liu, Fang Han. COL1A1: A novel oncogenic gene and therapeutic target in malignancies. Pathology - Research and Practice 2022; 236: 154013 doi: 10.1016/j.prp.2022.154013
|
| 31 |
Biao Niu, Sidong Wei, Jianjun Sun, Huibo Zhao, Bing Wang, Guoyong Chen. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation. Pharmaceutical Biology 2022; 60(1): 75 doi: 10.1080/13880209.2021.2017468
|
| 32 |
Francesca Matilde Schipilliti, Ingrid Garajová, Giulia Rovesti, Rita Balsano, Federico Piacentini, Massimo Dominici, Fabio Gelsomino. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals 2021; 14(1): 43 doi: 10.3390/ph14010043
|
| 33 |
Keisuke Koroki, Sadahisa Ogasawara, Yoshihiko Ooka, Hiroaki Kanzaki, Kengo Kanayama, Susumu Maruta, Takahiro Maeda, Masayuki Yokoyama, Toru Wakamatsu, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Satoshi Kuboki, Masayuki Ohtsuka, Masaru Miyazaki, Osamu Yokosuka, Naoya Kato. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020; 9(5): 596 doi: 10.1159/000508809
|
| 34 |
Xuhua Duan, Hao Li, Manzhou Wang, Shuguang Ju, Fengyao Li, Pengfei Chen, Huibin Lu, Xinwei Han, Jianzhuang Ren. PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma. Cell Death Discovery 2021; 7(1) doi: 10.1038/s41420-021-00585-y
|
| 35 |
Huancheng Wang, Jia Liu. Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma. Frontiers in Genetics 2020; 11 doi: 10.3389/fgene.2020.577000
|
| 36 |
Alessandro Granito, Sara Marinelli, Antonella Forgione, Matteo Renzulli, Francesca Benevento, Fabio Piscaglia, Francesco Tovoli. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma 2021; : 477 doi: 10.2147/JHC.S251729
|
| 37 |
Maria Tampaki, Evangelos Ionas, Emilia Hadziyannis, Melanie Deutsch, Katerina Malagari, John Koskinas. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers 2020; 12(1): 212 doi: 10.3390/cancers12010212
|
| 38 |
Masatoshi Kudo. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 2020; 9(2): 119 doi: 10.1159/000505189
|
| 39 |
Masatoshi Kudo. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020; 9(5): 479 doi: 10.1159/000509554
|
| 40 |
Masatoshi Kudo. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers 2020; 12(5): 1089 doi: 10.3390/cancers12051089
|
| 41 |
Jisoo Song, Jiyeon Ham, Taeyeon Hong, Gwonhwa Song, Whasun Lim. Fraxetin Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Human Hepatocellular Carcinoma Cell Lines Huh7 and Hep3B. Pharmaceutics 2021; 13(1): 112 doi: 10.3390/pharmaceutics13010112
|
| 42 |
Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines 2021; 9(5): 532 doi: 10.3390/vaccines9050532
|
| 43 |
Yue Hu, Tingting Qin, Shuang Li, Tao Zhang, Jun Xue. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.01589
|
| 44 |
Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.980214
|
| 45 |
Alessandro Granito, Antonella Forgione, Sara Marinelli, Matteo Renzulli, Luca Ielasi, Vito Sansone, Francesca Benevento, Fabio Piscaglia, Francesco Tovoli. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211016959
|
| 46 |
Junxiao Wang, Rui Liu, Yun Zhao, Zhenhu Ma, Zejie Sang, Zhenyu Wen, Xueling Yang, Hui Xie. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.743055
|
| 47 |
Masahiko Kinoshita, Daiju Ueda, Toshimasa Matsumoto, Hiroji Shinkawa, Akira Yamamoto, Masatsugu Shiba, Takuma Okada, Naoki Tani, Shogo Tanaka, Kenjiro Kimura, Go Ohira, Kohei Nishio, Jun Tauchi, Shoji Kubo, Takeaki Ishizawa. Deep Learning Model Based on Contrast-Enhanced Computed Tomography Imaging to Predict Postoperative Early Recurrence after the Curative Resection of a Solitary Hepatocellular Carcinoma. Cancers 2023; 15(7): 2140 doi: 10.3390/cancers15072140
|
| 48 |
Akihisa Ueno, Yohei Masugi, Ken Yamazaki, Yutaka Kurebayashi, Hanako Tsujikawa, Kathryn Effendi, Hidenori Ojima, Michiie Sakamoto. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. Pathology International 2020; 70(3): 140 doi: 10.1111/pin.12895
|
| 49 |
Lirui Dai, Zian Li, Yiran Tao, Wulong Liang, Weihua Hu, Shaolong Zhou, Xudong Fu, Xinjun Wang. Emerging roles of suppressor of cytokine signaling 3 in human cancers. Biomedicine & Pharmacotherapy 2021; 144: 112262 doi: 10.1016/j.biopha.2021.112262
|
| 50 |
Hiroji Shinkawa, Shogo Tanaka, Daijiro Kabata, Shigekazu Takemura, Ryosuke Amano, Kenjiro Kimura, Masahiko Kinoshita, Shoji Kubo. The Prognostic Impact of Tumor Differentiation on Recurrence and Survival after Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size. Liver Cancer 2021; 10(5): 461 doi: 10.1159/000517992
|
| 51 |
Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda. Systematic Literature Review of Trials Assessing Recommended Systemic Treatments in Hepatocellular Carcinoma. Hepatic Oncology 2022; 9(1) doi: 10.2217/hep-2021-0003
|
| 52 |
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos López López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. Journal of Hepatology 2023; 78(1): 133 doi: 10.1016/j.jhep.2022.09.006
|
| 53 |
Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduction and Targeted Therapy 2025; 10(1) doi: 10.1038/s41392-024-02075-w
|
| 54 |
Hong Zhao, Yujie Wang, Yufeng Liu, Xiaohua Hao, Hongshan Wei, Wen Xie. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. Analytical Cellular Pathology 2019; 2019: 1 doi: 10.1155/2019/5901083
|
| 55 |
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?. Livers 2022; 2(4): 315 doi: 10.3390/livers2040024
|
| 56 |
Zhanwang Xiang, Guohong Li, Luwen Mu, Haofan Wang, Churen Zhou, Huzheng Yan, Mingsheng Huang. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm). Technology in Cancer Research & Treatment 2023; 22 doi: 10.1177/15330338231200320
|
| 57 |
Dmitrij Ostroumov, Steven Duong, Jessica Wingerath, Norman Woller, Michael P. Manns, Kai Timrott, Moritz Kleine, Wolf Ramackers, Stephanie Roessler, Sven Nahnsen, Stefan Czemmel, Oliver Dittrich‐Breiholz, Tobias Eggert, Florian Kühnel, Thomas C. Wirth. Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer. Hepatology 2021; 73(4): 1399 doi: 10.1002/hep.31466
|
| 58 |
Mingye Zhao, Xingming Pan, Yue Yin, Hongfei Hu, Jifu Wei, Zhaoshi Bai, Wenxi Tang. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Frontiers in Public Health 2022; 10 doi: 10.3389/fpubh.2022.869960
|
| 59 |
Run Zhang, Yutong Yao, Hanwei Gao, Xin Hu. Mechanisms of angiogenesis in tumour. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1359069
|
| 60 |
Johannes Maximilian Ludwig, Michael Cecchini, Hyun S. Kim. Image-Guided Interventions in Oncology. 2020; : 371 doi: 10.1007/978-3-030-48767-6_21
|
| 61 |
Qiangqiang Zhong, Baokang Zhao, Xiao She, Xiangjie Liu, Xiaosheng Tan. HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation. PLOS ONE 2024; 19(11): e0311204 doi: 10.1371/journal.pone.0311204
|
| 62 |
Luc Defreyne. Interventional radiology for liver diseases. European Radiology 2021; 31(4): 2227 doi: 10.1007/s00330-020-07356-w
|
| 63 |
Hon-Ping Ma, Hang-Lung Chang, Oluwaseun Adebayo Bamodu, Vijesh Kumar Yadav, Ting-Yi Huang, Alexander T. H. Wu, Chi-Tai Yeh, Shin-Han Tsai, Wei-Hwa Lee. Collagen 1A1 (COL1A1) Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and Metastasis. Cancers 2019; 11(6): 786 doi: 10.3390/cancers11060786
|
| 64 |
Ann-Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology 2020; 72(2): 307 doi: 10.1016/j.jhep.2019.09.025
|
| 65 |
Katharina Pomej, Bernhard Scheiner, Dabin Park, David Bauer, Lorenz Balcar, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Christian Müller, Michael Trauner, Matthias Pinter. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers 2020; 12(10): 2961 doi: 10.3390/cancers12102961
|
| 66 |
Thomas Helmberger. The evolution of interventional oncology in the 21st century. The British Journal of Radiology 2020; 93(1113) doi: 10.1259/bjr.20200112
|
| 67 |
Long Yang, Pinsheng Han, Tao Cui, Yu Miao, Tianyu Zhao, Zilin Cui, Yijia Chen, Hao Chi, Jieying Zhang, Yamin Zhang. M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1251648
|
| 68 |
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
|
| 69 |
Masatoshi Kudo. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020; 9(6): 640 doi: 10.1159/000511001
|
| 70 |
Yi Luo, Lei Song, Xinyu Wang, Yujie Huang, Yongqiang Liu, Qi Wang, Ming Hong, Zhongyu Yuan. Uncovering the Mechanisms of Cryptotanshinone as a Therapeutic Agent Against Hepatocellular Carcinoma. Frontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.01264
|
| 71 |
Anne Dyhl-Polk, Marta Kramer Mikkelsen, Morten Ladekarl, Dorte Lisbet Nielsen. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Journal of Clinical Medicine 2021; 10(12): 2662 doi: 10.3390/jcm10122662
|
| 72 |
Payal Deepak, Rajinikanth Siddalingam, Praveen Kumar, Sneha Anand, Sunita Thakur, Balasubramaniam Jagdish, Shweta Jaiswal. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020; 59: 101837 doi: 10.1016/j.jddst.2020.101837
|
| 73 |
Shun-Zhen Zheng, Ping Sun, Jian-Ping Wang, Yong Liu, Wei Gong, Jun Liu. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World Journal of Gastroenterology 2019; 25(22): 2752-2762 doi: 10.3748/wjg.v25.i22.2752
|
| 74 |
Fat-Moon Suk, Chao-Lien Liu, Ming-Hua Hsu, Yu-Ting Chuang, Jack P. Wang, Yi-Jen Liao. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-53863-2
|
| 75 |
Ziyu Liu, Yan Lin, Jinyan Zhang, Yumei Zhang, Yongqiang Li, Zhihui Liu, Qian Li, Ming Luo, Rong Liang, Jiazhou Ye. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1412-8
|
| 76 |
Pei-Chang Lee, Yee Chao, Ming-Huang Chen, Keng-Hsin Lan, Chieh-Ju Lee, I-Cheng Lee, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers 2020; 12(1): 182 doi: 10.3390/cancers12010182
|
| 77 |
Su Jong Yu, Tim F. Greten. Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. Journal of Liver Cancer 2020; 20(1): 1 doi: 10.17998/jlc.20.1.1
|
| 78 |
Hiroji Shinkawa, Shogo Tanaka, Shigekazu Takemura, Ryosuke Amano, Kenjiro Kimura, Masahiko Kinoshita, Toru Miyazaki, Shoji Kubo. Prognostic value of expanded liver transplantation criteria—the 5‐5‐500 rule—in patients with hepatic resection for intermediate‐stage hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2020; 27(10): 682 doi: 10.1002/jhbp.792
|
| 79 |
Howard Lim, Ravi Ramjeesingh, Dave Liu, Vincent C Tam, Jennifer J Knox, Paul B Card, Brandon M Meyers. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. JNCI: Journal of the National Cancer Institute 2021; 113(2): 123 doi: 10.1093/jnci/djaa119
|
| 80 |
Jin-Ping Qian, Bing Jiang, Xu-Dong Lei, Le-Le Tian, Ying Zhou, Jing-Quan Teng, Jia Yue, Jin-Juan Li, Yan Zhang. Influence of gut microecology in the development of malignant tumors and its potential therapeutic application: A review. Medicine 2023; 102(27): e34274 doi: 10.1097/MD.0000000000034274
|
| 81 |
Yoshito Tomimaru, Arihiro Aihara, Jack R. Wands, Costica Aloman, Miran Kim. A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform. Translational Oncology 2019; 12(10): 1345 doi: 10.1016/j.tranon.2019.07.002
|
| 82 |
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1070961
|
| 83 |
Liting wang, Ye Peng, Shuxia Qin, Xiaomin Wan, Xiaohui Zeng, Sini Li, Qiao Liu, Chongqing Tan, Daniele Ugo Tari. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PLOS ONE 2023; 18(4): e0279786 doi: 10.1371/journal.pone.0279786
|
| 84 |
Nikola Bošković, Branislav Radjenović, Srdjan Nikolić, Marija Radmilović-Radjenović. Effectiveness of microwave ablation using two simultaneous antennas for liver malignancy treatment. Open Physics 2024; 22(1) doi: 10.1515/phys-2024-0079
|
| 85 |
Atsushi Ono, Hiroshi Aikata, Masami Yamauchi, Kenichiro Kodama, Waka Ohishi, Takeshi Kishi, Kazuki Ohya, Yuji Teraoka, Mitsutaka Osawa, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Daiki Miki, Tomokazu Kawaoka, Hiromi Abe-Chayama, Peiyi Zhang, Songyao Liu, Grace Naswa Makokha, Masataka Tsuge, Michio Imamura, C. Nelson Hayes, Kazuaki Chayama. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Therapeutic Advances in Medical Oncology 2020; 12 doi: 10.1177/1758835920922051
|
| 86 |
Na Li, Lianxiang Luo, Jiaen Wei, Yong Liu, Neshatul Haque, Hongbin Huang, Yi Qi, Zunnan Huang. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma. International Journal of Biological Macromolecules 2021; 182: 910 doi: 10.1016/j.ijbiomac.2021.04.081
|
| 87 |
|
| 88 |
Flavia Fondevila, Carolina Méndez-Blanco, Paula Fernández-Palanca, Javier González-Gallego, José L. Mauriz. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Experimental & Molecular Medicine 2019; 51(9): 1 doi: 10.1038/s12276-019-0308-1
|
| 89 |
Huisi Liu, Sanduo Zheng, Xinfeng Hou, Ximing Liu, Kaixin Du, Xueyuan Lv, Yulu Li, Fang Yang, Wenhui Li, Jianhua Sui. Novel Abs targeting the N‐terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile‐acid‐related side‐effects. Cancer Science 2020; 111(5): 1750 doi: 10.1111/cas.14353
|
| 90 |
Meijuan Zheng, Zhigang Tian. Liver-Mediated Adaptive Immune Tolerance. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02525
|
| 91 |
Kei Moriya, Tadashi Namisaki, Hiroaki Takaya, Kosuke Kaji, Hideto Kawaratani, Naotaka Shimozato, Yasuhiko Sawada, Akitoshi Douhara, Shinya Sato, Masanori Furukawa, Koh Kitagawa, Takemi Akahane, Hitoshi Yoshiji. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. Journal of Clinical Medicine 2021; 10(4): 629 doi: 10.3390/jcm10040629
|
| 92 |
Md Gulam Musawwir Khan, Amit Ghosh, Bhavesh Variya, Madanraj Appiya Santharam, Awais Ullah Ihsan, Sheela Ramanathan, Subburaj Ilangumaran. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07285-3
|
| 93 |
|
| 94 |
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
|
| 95 |
Sheng-Han Wang, Shiou-Hwei Yeh, Pei-Jer Chen. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers 2021; 13(10): 2454 doi: 10.3390/cancers13102454
|
| 96 |
Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?. World Journal of Transplantation 2020; 10(11): 297-306 doi: 10.5500/wjt.v10.i11.297
|
| 97 |
Yue Zhao, Jiaxu Wang, Wai Nam Liu, Shin Yie Fong, Timothy Wai Ho Shuen, Min Liu, Sarah Harden, Sue Yee Tan, Jia Ying Cheng, Wilson Wei Sheng Tan, Jerry Kok Yen Chan, Cheng Ean Chee, Guan Huei Lee, Han Chong Toh, Seng Gee Lim, Yue Wan, Qingfeng Chen. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model. Hepatology 2021; 74(3): 1395 doi: 10.1002/hep.31812
|
| 98 |
Yih-Giun Cherng, Yi Cheng Chu, Vijesh Kumar Yadav, Ting-Yi Huang, Ming-Shou Hsieh, Kwai-Fong Lee, Wei-Hwa Lee, Chi-Tai Yeh, Jiann Ruey Ong. Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness. Cancers 2021; 13(11): 2755 doi: 10.3390/cancers13112755
|
| 99 |
Xiongfeng Pan, Atipatsa C Kaminga, Shi Wu Wen, Aizhong Liu. Chemokines in hepatocellular carcinoma: a meta-analysis. Carcinogenesis 2020; 41(12): 1682 doi: 10.1093/carcin/bgaa106
|
| 100 |
Mohamedraed Elshami, Richard Hoehn, Jonathan J. Hue, Luke Rothermel, Kenneth D. Chavin, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter, Lee M. Ocuin. Medicaid expansion is associated with a higher likelihood of early diagnosis, resection, transplantation, and overall survival in patients with hepatocellular carcinoma. HPB 2022; 24(9): 1482 doi: 10.1016/j.hpb.2022.03.003
|
| 101 |
Laurys Boudin, Jean-Baptiste Morvan, Juliette Thariat, Denis Métivier, Pierre-Yves Marcy, David Delarbre. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. Current Oncology 2022; 29(10): 7718 doi: 10.3390/curroncol29100610
|
| 102 |
Tao Wei, Xu-Feng Zhang, Feng Xue, Fabio Bagante, Francesca Ratti, Hugo P. Marques, Silvia Silva, Olivier Soubrane, Vincent Lam, George A. Poultsides, Irinel Popescu, Razvan Grigorie, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Tom Hugh, Luca Aldrighetti, Itaru Endo, Timothy M. Pawlik. Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Annals of Surgical Oncology 2021; 28(12): 7624 doi: 10.1245/s10434-021-10142-7
|
| 103 |
Qiaoxin Wei, Haiyang Zhou, Xinhui Hou, Xiaoping Liu, Sisi Chen, Xueying Huang, Yu Chen, Mei Liu, Zhongping Duan. Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02425-4
|
| 104 |
Eishiro Mizukoshi, Shuichi Kaneko. Immune cell therapy for hepatocellular carcinoma. Journal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-019-0742-5
|
| 105 |
D. G. Akhaladze, G. S. Rabaev. Pediatric hepatocellular carcinoma - the main differences from adult patients. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery 2020; 25(4): 85 doi: 10.16931/1995-5464.2020485-94
|
| 106 |
Wenwen Zhang, Bingyang Hu, Jun Han, Zhanbo Wang, Guangyu Ma, Huiyi Ye, Jing Yuan, Junning Cao, Ze Zhang, Jihang Shi, Mingyi Chen, Xun Wang, Yinzhe Xu, Yanshuang Cheng, Lantian Tian, Hongguang Wang, Shichun Lu. Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.747950
|
| 107 |
Petros Fessas, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Uqba Khan, ChiehJu Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Francesca Benevento, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Yi-Hsiang Huang, Lorenza Rimassa, Celina Ang, Thomas Marron, David J Pinato. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001033 doi: 10.1136/jitc-2020-001033
|
| 108 |
Chunye Zhang, Ming Yang, Aaron C. Ericsson. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.524205
|
| 109 |
Naomi Suzuki, Kazuto Tajiri, Yuka Futsukaichi, Shinichi Tanaka, Aiko Murayama, Toshiki Entani, Saito Kobayashi, Kosuke Takahashi, Tsutomu Fujii, Johji Imura, Ichiro Yasuda. Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma. Case Reports in Gastroenterology 2020; 14(1): 63 doi: 10.1159/000505774
|
| 110 |
Marcin Cybulski, Magdalena Zaremba-Czogalla, Bartosz Trzaskowski, Marek Kubiszewski, Joanna Tobiasz, Anna Jaromin, Piotr Krzeczyński, Jerzy Gubernator, Olga Michalak. The conjugates of 5′-deoxy-5-fluorocytidine and hydroxycinnamic acids – synthesis, anti-pancreatic cancer activity and molecular docking studies. RSC Advances 2024; 14(19): 13129 doi: 10.1039/D4RA01683A
|
| 111 |
Feng Wen, Hanrui Zheng, Pengfei Zhang, Weiting Liao, Kexun Zhou, Qiu Li. Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states. Liver International 2021; 41(5): 1097 doi: 10.1111/liv.14795
|
| 112 |
Guhe Jia, Lupeng Qiu, Hongye Zheng, Boyu Qin, Zhuoya Sun, Yangyang Shao, Zizhong Yang, Jiakang Shao, Yuxin Zhou, Shunchang Jiao. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11064-1
|
| 113 |
Zhigang Fu, Xiaowei Li, Jiaming Zhong, Xiaoxia Chen, Kunkun Cao, Ning Ding, Li Liu, Xiaoli Zhang, Jian Zhai, Zengqiang Qu. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatology International 2021; 15(3): 663 doi: 10.1007/s12072-021-10184-9
|
| 114 |
Hansen Dang, Yee Hui Yeo, Satoshi Yasuda, Chung‐Feng Huang, Etsuko Iio, Charles Landis, Dae Won Jun, Masaru Enomoto, Eiichi Ogawa, Pei‐Chien Tsai, An Le, Matthew Liu, Mayumi Maeda, Brian Nguyen, Nathan Ramrakhiani, Linda Henry, Ramsey Cheung, Akihiro Tamori, Takashi Kumada, Yasuhito Tanaka, Ming‐Lung Yu, Hidenori Toyoda, Mindie H. Nguyen. Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020; 71(6): 1910 doi: 10.1002/hep.30988
|
| 115 |
Yuting Lu, Jiangtao Jin, Qi Du, Min Hu, Yuhan Wei, Miao Wang, Hongzhong Li, Qin Li. Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.730240
|